Mitchell L. Henry
YOU?
Author Swipe
View article: Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study
Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study Open
Objectives Development of pharmaceutical agents in transplantation is currently limited by long waits for hard endpoints. We applied a validated integrative risk-prognostication system integrative Box (iBox) as a surrogate endpoint to the …
View article: Wound healing adverse events in kidney transplant recipients receiving everolimus with reduced calcineurin inhibitor exposure or current standard-of-care: insights from the 24-month TRANSFORM study
Wound healing adverse events in kidney transplant recipients receiving everolimus with reduced calcineurin inhibitor exposure or current standard-of-care: insights from the 24-month TRANSFORM study Open
NCT01950819.
View article: Misrepresentation of Females: Gender Stereotypes in Popular Film
Misrepresentation of Females: Gender Stereotypes in Popular Film Open
This study analyzes how gender is portrayed throughout the 150 top-grossing animated films (1990-2019).
View article: “Early” and “Late” Hospital readmissions in the first year after kidney transplant at a single center
“Early” and “Late” Hospital readmissions in the first year after kidney transplant at a single center Open
Background Hospital readmission (HR) after surgery is considered a quality metric. Methods Data on 2371 first‐time adult kidney transplant (KT) recipients were collected to analyze the “early” (≤30 days) and “late” (31‐365 days) HR pattern…
View article: Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study
Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study Open
TRANSFORM (TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen) was a 24-month, prospective, open-label trial in 2037 de novo renal transplant recipients randomized (1:1) within 24 hours of transplantation to receive e…
View article: Use of donors at age extremes for simultaneous pancreas-kidney transplant
Use of donors at age extremes for simultaneous pancreas-kidney transplant Open
Introduction: There is a shortage of optimal pancreatic donors for simultaneous pancreas and kidney transplant (SPKT), as such there is interest in utilizing donors at extremes of age to expand the donor pool. We sought to evaluate outcome…
View article: Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation
Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation Open
Background Everolimus permits reduced calcineurin inhibitor (CNI) exposure, but the efficacy and safety outcomes of this treatment after kidney transplant require confirmation. Methods In a multicenter noninferiority trial, we randomized 2…
View article: Exocrine drainage of the transplanted pancreas: A review
Exocrine drainage of the transplanted pancreas: A review Open
Pancreas transplant is an important treatment option for insulin dependent diabetic patients as it may result in physiologic euglycemia. Improvements in surgical technique, graft preservation, immunosuppression, diagnosis and management of…
View article: Refractory Hypotension after Liver Allograft Reperfusion: A Case of Dynamic Left Ventricular Outflow Tract Obstruction
Refractory Hypotension after Liver Allograft Reperfusion: A Case of Dynamic Left Ventricular Outflow Tract Obstruction Open
Hypotension after reperfusion is a common occurrence during liver transplantation following the systemic release of cold, hyperkalemic, and acidic contents of the liver allograft. Moreover, the release of vasoactive metabolites such as inf…